Related Experiment Videos
A new method of long-term preventive cardioprotection using Lactobacillus
1Heart Institute, Chaim Sheba Medical Center, Tel Hashomer, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 69978, Israel 84105, USA.
Summary
Lactobacillus cultivation components (LCC) offer long-term cardioprotection against heart damage from ischemia-reperfusion. This protection involves activating cellular defense systems and is sustained for at least 21 days.
Area of Science:
- Cardiology
- Biochemistry
- Pharmacology
Background:
- Ischemia-reperfusion injury remains a significant cause of heart damage.
- Developing effective cardioprotective strategies is crucial for managing ischemic heart syndromes.
Purpose of the Study:
- To investigate the potential long-term cardioprotective effects of Lactobacillus cultivation components (LCC).
- To elucidate the underlying mechanisms of LCC-induced cardioprotection against ischemia-reperfusion injury.
Main Methods:
- Anesthetized rats received intravenous Lactobacillus cultivation components (LCC) or saline at 1, 7, and 21 days before inducing global ischemia (GI) via 20-minute flow stop in isolated Langendorff-perfused hearts.
- Functional recovery, reperfusion tachyarrhythmia, norepinephrine (NE) and prostacyclin release, myocardial catalase activity, and heat stress protein 70 (HSP-70) expression were assessed.
Main Results:
- LCC significantly reduced reperfusion tachyarrhythmia and improved functional recovery of the ischemized rat heart.
- Beneficial effects were linked to reduced NE and prostacyclin release, activated myocardial catalase, and HSP-70 overexpression.
- Cardioprotection was observed up to 21 days after a single LCC administration.
Conclusions:
- Lactobacillus cultivation components (LCC) demonstrate significant, long-term cardioprotection against ischemia-reperfusion damage.
- The protective effects are attributed to the activation of cellular defense mechanisms, including antioxidant pathways and protective protein expression.
- Norepinephrine and prostacyclin appear to be involved in the LCC-mediated cardioprotective process, warranting further investigation for therapeutic potential in ischemic heart syndromes.